Amgen Inc. has announced the rapid acceleration of its clinical trial program for obesity, marking it as one of the largest in the company's 45-year history. The investigational medicine, maridebart cafraglutide, also known as MariTide, is at the center of the Phase 3 MARITIME program. This program aims to evaluate the safety and efficacy of MariTide for the treatment of obesity and obesity-related conditions. The MARITIME program includes MARITIME-1, a study focused on individuals with overweight or obesity, and MARITIME-2, which targets those living with type 2 diabetes and overweight or obesity. The results of these trials have not yet been presented. Further updates and information about the Phase 3 clinical program can be accessed through the MARITIME website.